INDIANAPOLIS — Today, the very first authorized treatment for Canine Parvovirus (Parvo) was hand provided to IndyHumane to help fight the fatal infection.
Recently, Elanco Animal Health received conditional approval for Canine Parvovirus Monoclonal Antibody by the USDA. This is the very first and only treatment for canine parvovirus.
On Tuesday, Elanco CEO Jeff Simmons hand provided among the very first containers of this life conserving treatment to IndyHumane.
According to IndyHumane, they have actually seen 46 cases of Parvovirus this year already.
Canine parvovirus is among the most dangerous illness to impact dogs – particularly puppies. There are an approximated 330,000 cases of canine parvovirus in the U.S. each year.
“To have actually a treatment like this to help those animals out there that have not been immunized is going to be lifesaving,” IndyHumane CEO Donna Casamento said.
The Canine Parvovirus Monoclonal Antibody treatment might supply a less extensive and more efficient service than encouraging care alone for Parvovirus.